<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="170">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04534712</url>
  </required_header>
  <id_info>
    <org_study_id>yet to be assigned</org_study_id>
    <nct_id>NCT04534712</nct_id>
  </id_info>
  <brief_title>Lymphocyte - Monocyte Ratio As An Independent Predictor For Progression Of Illness In Patients With Covid-19</brief_title>
  <official_title>Lymphocyte - Monocyte Ratio As An Independent Predictor For Progression Of Illness In Patients With Covid-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Postgraduate Institute of Medical Education and Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sir Ganga Ram Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Postgraduate Institute of Medical Education and Research</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Corona virus disease 2019 (COVID 19), first identified in December 2019 in a cluster of
      population in a Chinese province, soon emerged as a pandemic, causing a huge strain on
      healthcare system and mortality all over the world. An ideal marker for predicting course of
      this illness should be easily available and reproducible; as the disease burden has spread to
      third world countries whose healthcare system is resource limited. Our study is aimed to
      study the utility of lymphocyte- monocyte ratio in the early stages to predict the
      progression of COVID 19 pneumonia.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">February 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>progression</measure>
    <time_frame>28 days</time_frame>
    <description>disease progression equal or more than 2 stages</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>mortality</measure>
    <time_frame>28 days</time_frame>
    <description>end outcome of the patients diagnosed of COVID-19 infection</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>PROGRESSION</arm_group_label>
    <description>Cohort A with patients who progressed to next stage of illness or continue to remain in the same stage</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NON PROGRESSION</arm_group_label>
    <description>Cohort B with those who improved by two points on the ordinal scale without any further progression</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>LYMPHOCYTE MONOCYTE RATIO</intervention_name>
    <description>Absolute lymphicyte and absolute monocyte counts are recorded on admission of COVID -19 positive patient and ratio is derived. the patients are followed up for any progression of disease stage.</description>
    <arm_group_label>NON PROGRESSION</arm_group_label>
    <arm_group_label>PROGRESSION</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        all patients who are tested positive for COVID 19 and presented within 7 days of symptom
        onset will be included
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All adults of age 18-80 years tested positive for SARS-CoV-2 reverse-transcriptase -
             polymerase chain reaction (rt-PCR) and presented within 7 days of symptom(s) onset

        Exclusion Criteria:

          -  Pregnancy

          -  Sepsis

          -  Malignancy

          -  Patients on immunosuppressant therapy

          -  Chronic inflammatory conditions

          -  Cases lost to follow up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>vamsidhar amburu, MD</last_name>
    <phone>+919814866818</phone>
    <email>rahdismav_a@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sir Ganga Ram Hospital</name>
      <address>
        <city>New delhi</city>
        <state>Delhi</state>
        <zip>110060</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 30, 2020</study_first_submitted>
  <study_first_submitted_qc>August 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 1, 2020</study_first_posted>
  <last_update_submitted>August 30, 2020</last_update_submitted>
  <last_update_submitted_qc>August 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sir Ganga Ram Hospital</investigator_affiliation>
    <investigator_full_name>VAMSIDHAR</investigator_full_name>
    <investigator_title>DNB Trainee</investigator_title>
  </responsible_party>
  <keyword>LYMPHOCYTE MONOCYTE RATIO</keyword>
  <keyword>COVID-19</keyword>
  <keyword>DISEASE PROGRESSION</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease Progression</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD data shall be shared on request basis.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>1 year from the study completion till publication</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

